XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.21.1

REVENUE (Tables) | 6 Months Ended
--- | ---
Apr. 30, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended April 30,
| 2021 |  | 2020
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 231 |  |  | $ | 187 |  |  | $ | 163 |  |  | $ | 581 |  |  | $ | 170 |  |  | $ | 161 |  |  | $ | 126 |  |  | $ | 457 |
Europe | 155 |  |  | 154 |  |  | 106 |  |  | 415 |  |  | 111 |  |  | 131 |  |  | 92 |  |  | 334 |
Asia Pacific | 288 |  |  | 195 |  |  | 46 |  |  | 529 |  |  | 245 |  |  | 157 |  |  | 45 |  |  | 447 |
Total | $ | 674 |  |  | $ | 536 |  |  | $ | 315 |  |  | $ | 1,525 |  |  | $ | 526 |  |  | $ | 449 |  |  | $ | 263 |  |  | $ | 1,238 |
| Six Months Ended April 30,
| 2021 |  | 2020
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 455 |  |  | $ | 366 |  |  | $ | 315 |  |  | $ | 1,136 |  |  | $ | 379 |  |  | $ | 328 |  |  | $ | 244 |  |  | $ | 951 |
Europe | 345 |  |  | 301 |  |  | 206 |  |  | 852 |  |  | 278 |  |  | 264 |  |  | 184 |  |  | 726 |
Asia Pacific | 596 |  |  | 401 |  |  | 88 |  |  | 1,085 |  |  | 507 |  |  | 327 |  |  | 84 |  |  | 918 |
Total | $ | 1,396 |  |  | $ | 1,068 |  |  | $ | 609 |  |  | $ | 3,073 |  |  | $ | 1,164 |  |  | $ | 919 |  |  | $ | 512 |  |  | $ | 2,595 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Six Months Ended
| April 30, |  | April 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
| (in millions) |  |  |  |
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 531 |  |  | $ | 400 |  |  | $ | 1,052 |  |  | $ | 823 |
Chemical and Energy | 314 |  |  | 267 |  |  | 642 |  |  | 579 |
Diagnostics and Clinical | 233 |  |  | 200 |  |  | 449 |  |  | 394 |
Food | 144 |  |  | 114 |  |  | 306 |  |  | 244 |
Academia and Government | 143 |  |  | 115 |  |  | 285 |  |  | 256 |
Environmental and Forensics | 160 |  |  | 142 |  |  | 339 |  |  | 299 |
Total | $ | 1,525 |  |  | $ | 1,238 |  |  | $ | 3,073 |  |  | $ | 2,595 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 632 |  |  | $ | 491 |  |  | $ | 1,313 |  |  | $ | 1,084 |
Non-instrumentation and other | 893 |  |  | 747 |  |  | 1,760 |  |  | 1,511 |
Total | $ | 1,525 |  |  | $ | 1,238 |  |  | $ | 3,073 |  |  | $ | 2,595 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2021:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2020 |  | $ | 446 |
Net revenue deferred in the period |  | 304 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (267) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 7 |
Currency translation and other adjustments |  | 7 |
Ending balance as of April 30, 2021 |  | $ | 497 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration